BSE Live
Oct 10, 16:01Prev. Close
1118.95
Open Price
1125.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 10, 15:56Prev. Close
1119.90
Open Price
1125.40
Bid Price (Qty.)
1130.30 (523)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Aurobindo Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 8,167.75 | 7,208.39 | 5,497.31 | 4,301.88 | 4,178.31 | |
Less: Excise/Sevice Tax/Other Levies | 149.74 | 158.82 | 144.40 | 97.28 | 96.87 | |
Revenue From Operations [Net] | 8,018.01 | 7,049.57 | 5,352.91 | 4,204.60 | 4,081.44 | |
Total Operating Revenues | 8,095.10 | 7,110.71 | 5,425.10 | 4,281.45 | 4,133.12 | |
Other Income | 67.22 | 74.80 | 26.51 | 19.06 | 57.01 | |
Total Revenue | 8,162.32 | 7,185.51 | 5,451.61 | 4,300.51 | 4,190.13 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 3,920.33 | 3,422.34 | 3,053.64 | 2,393.29 | 2,328.63 | |
Purchase Of Stock-In Trade | 15.76 | 96.89 | 78.09 | 35.52 | 8.53 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -159.09 | -35.75 | -121.08 | 89.87 | -136.38 | |
Employee Benefit Expenses | 668.75 | 514.21 | 431.42 | 364.10 | 303.60 | |
Finance Costs | 132.14 | 288.84 | 250.06 | 267.58 | 55.02 | |
Depreciation And Amortisation Expenses | 245.15 | 185.97 | 171.39 | 142.94 | 125.04 | |
Other Expenses | 1,398.93 | 1,193.55 | 1,024.97 | 825.17 | 671.53 | |
Total Expenses | 6,221.97 | 5,666.05 | 4,888.49 | 4,118.47 | 3,355.97 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,940.35 | 1,519.46 | 563.12 | 182.04 | 834.16 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | -319.86 | -28.71 | |
Profit/Loss Before Tax | 1,940.35 | 1,519.46 | 563.12 | -137.82 | 805.45 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 420.63 | 334.62 | 126.50 | 4.87 | 183.75 | |
Less: MAT Credit Entitlement | 9.95 | 124.56 | 126.50 | 0.00 | 0.00 | |
Deferred Tax | 13.32 | 137.31 | 64.15 | -118.03 | 26.75 | |
Tax For Earlier Years | 0.00 | 0.00 | 2.98 | 17.95 | 1.15 | |
Total Tax Expenses | 424.00 | 347.37 | 67.13 | -95.21 | 211.65 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,516.35 | 1,172.09 | 495.99 | -42.61 | 593.80 | |
Profit/Loss From Continuing Operations | 1,516.35 | 1,172.09 | 495.99 | -42.61 | 593.80 | |
Profit/Loss For The Period | 1,516.35 | 1,172.09 | 495.99 | -42.61 | 593.80 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 52.01 | 40.24 | 17.04 | -1.46 | 20.63 | |
Diluted EPS (Rs.) | 51.97 | 40.20 | 17.02 | -1.46 | 18.56 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 2,153.63 | 2,020.71 | 1,822.98 | 1,455.40 | 1,521.95 | |
Indigenous Raw Materials | 1,766.70 | 1,401.62 | 1,230.66 | 937.89 | 806.68 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 9.77 | 4.73 | 3.58 | 3.62 | 6.21 | |
Indigenous Stores And Spares | 106.20 | 71.00 | 57.24 | 60.84 | 48.29 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 131.28 | 87.41 | 43.68 | 29.11 | 58.72 | |
Tax On Dividend | 25.04 | 14.85 | 7.20 | 4.72 | 9.64 | |
Equity Dividend Rate (%) | 300.00 | 300.00 | 150.00 | 100.00 | 200.00 |
09.10.2025
11.09.2025
Aurobindo Pharma shares rise 4.5% as report says GTCR strikes $4.8-bn deal to buy Zentiva
08.09.2025
Aurobindo Pharma shares fall on eight observations from USFDA
08.09.2025
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
27.05.2025
Aurobindo Pharm Standalone March 2025 Net Sales at Rs 2,731.99 crore, down 5.6% Y-o-Y
12.02.2025
Aurobindo Pharm Standalone December 2024 Net Sales at Rs 2,916.63 crore, up 8.34% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL